Early Life Exposure to Common Plastic Chemical Linked to Adult Anxiety in Rats

CHICAGO, IL – Male rats exposed to di-(2-ethylhexyl) phthalate (DEHP), a ubiquitous plasticizer found in countless consumer products, during critical early developmental stages exhibited significantly higher levels of anxiety in adulthood. This groundbreaking research, presented at ENDO 2026, the Endocrine Society’s annual meeting, offers compelling evidence that prenatal and early postnatal exposure to endocrine-disrupting chemicals (EDCs) can have lasting behavioral consequences, potentially extending to human populations.

The study, conducted by researchers at the University of Buenos Aires School of Medicine, meticulously investigated the impact of DEHP on the developing male rat brain and its subsequent influence on anxiety-related behaviors. The findings underscore a growing concern among scientists and public health officials regarding the pervasive presence of EDCs in our environment and their subtle yet profound effects on neurodevelopment.

The Pervasive Presence of DEHP

DEHP is a phthalate ester, a class of chemicals widely used to enhance the flexibility, durability, and transparency of plastics. Its widespread application means it is an integral component in a vast array of everyday items, from children’s toys and medical devices like intravenous tubing and blood bags, to flooring, shower curtains, and raincoats. Its presence in such a broad spectrum of consumer goods makes human exposure, particularly during vulnerable developmental periods, almost unavoidable.

Previous scientific investigations have already established DEHP as an endocrine disruptor, capable of interfering with the body’s hormonal systems. Research has indicated that DEHP and its metabolic byproducts can affect multiple organ systems in both animal models and humans, with particular emphasis on the reproductive and nervous systems. However, the precise mechanisms by which DEHP might influence complex behaviors like anxiety remained an area requiring further exploration. This latest research aimed to bridge that gap, focusing on the developmental window and the potential role of key neurotransmitters and hormones.

Unraveling the Neuroendocrine Connection

The research team, led by Osvaldo Juan Ponzo, M.D., Ph.D., a professor of physiology at the University of Buenos Aires School of Medicine, hypothesized that early-life exposure to DEHP could trigger long-term alterations in brain function, leading to increased anxiety. Their investigation specifically sought to determine if gamma-aminobutyric acid (GABA), a primary inhibitory neurotransmitter in the central nervous system, or testosterone, a key sex hormone, played a mediating role in these potential behavioral changes.

GABA is crucial for regulating neuronal excitability, essentially acting as the brain’s "brake pedal." It plays a vital role in dampening nerve activity, and imbalances in GABAergic signaling have been implicated in various neurological and psychiatric disorders, including anxiety. Testosterone, on the other hand, is known to influence brain development and function, with effects that can extend into adulthood and impact mood and behavior. Understanding the interplay between DEHP, GABA, and testosterone was central to deciphering the observed behavioral outcomes.

Experimental Design and Chronology of Exposure

The study meticulously followed a controlled experimental protocol to assess the impact of DEHP exposure during critical developmental phases. Pregnant female rats were administered daily oral doses of DEHP, commencing on the very first day of gestation and continuing throughout the entire period of pregnancy and lactation, until their offspring were weaned. This comprehensive exposure window was designed to mimic the continuous exposure that developing fetuses and newborns might experience in environments where DEHP is prevalent.

Following weaning, the male offspring were raised under standard laboratory conditions. The crucial assessment of their anxiety-related behaviors took place when the rats reached adulthood, specifically at 70 days of age. This adult stage was chosen to evaluate the persistence of any effects initiated during early development.

The Elevated Plus Maze: A Window into Anxiety

To quantitatively measure anxiety-related behavior, the researchers employed the elevated plus maze (EPM) test, a widely validated behavioral paradigm in rodent research. The EPM is designed to exploit rodents’ innate aversion to open, elevated spaces and their preference for enclosed, protected areas. The maze is shaped like a cross, featuring two enclosed arms and two open arms that extend from a central platform.

During the EPM test, the rats were observed and their behaviors meticulously recorded. Key metrics included the number of times each rat entered the open and enclosed arms, the total duration spent in each type of arm, and the amount of time spent exhibiting "freezing" behavior. Freezing, characterized by immobility, is a common stress response in rodents and is often indicative of heightened fear or anxiety. Rats that are less anxious tend to explore open areas more readily, whereas highly anxious rats will confine themselves to the safety of the enclosed arms and may freeze more frequently, reflecting their perceived threat level.

Decoding the Results: DEHP’s Anxiogenic Effect

The results of the EPM test revealed a clear and significant difference between the rats exposed to DEHP during early development and those that were not. The DEHP-exposed male rats exhibited pronounced signs of increased anxiety. They demonstrated a marked reluctance to explore the open arms of the maze, spending significantly less time in these exposed areas. Conversely, they preferentially remained within the enclosed arms, seeking perceived safety. Furthermore, these rats displayed a greater propensity for freezing behavior, indicating heightened fear and a more cautious response to the novel environment.

This behavioral pattern strongly suggests that early-life exposure to DEHP had induced a lasting state of heightened anxiety in the adult male rats, even though they did not receive DEHP exposure in adulthood. This finding is critical, as it points to a potential for long-term neurobiological programming that can alter an individual’s stress response and emotional regulation.

Reversal of Effects: The Role of GABA and Testosterone

Crucially, the researchers investigated whether the anxiogenic effects of DEHP could be mitigated. To this end, separate groups of DEHP-exposed rats were treated with either GABA agonists or testosterone prior to the EPM test. GABA agonists are compounds that mimic the action of GABA, binding to its receptors and enhancing its inhibitory effects. Testosterone was administered periodically to the rats.

The findings from these treatment groups were striking. Rats that received either GABA agonists or testosterone demonstrated a reversal of the anxiety-like behaviors observed in the DEHP-only exposed group. These treated rats showed a pattern more akin to control animals, exhibiting greater exploration of the open arms and less freezing behavior. This suggests that the anxiogenic effects of early DEHP exposure were, at least in part, mediated by disruptions in the GABAergic system and potentially influenced by testosterone levels or its signaling pathways.

"This work demonstrates that contact with DEHP in the early stages of life could modify behavior with regard to anxiety, even in the absence of DEHP exposure in adulthood," stated Dr. Ponzo. "These neuroendocrine changes can be reversed by treating with GABA agonists or testosterone." This statement highlights the plasticity of the developing brain and suggests that interventions targeting these specific neurochemical pathways might offer therapeutic potential for individuals experiencing anxiety linked to early-life EDC exposure.

Broader Implications and Future Directions

The implications of this research extend far beyond the laboratory rat. While direct extrapolation to humans requires further investigation, the study provides a robust animal model for understanding the potential risks posed by DEHP and similar EDCs to human neurodevelopment. Endocrine Society meetings are often platforms for presenting research that informs public health policy and scientific understanding of hormonal disruption. The presentation of these findings at ENDO 2026 signifies their importance within the endocrine research community.

The widespread human exposure to DEHP, particularly during pregnancy and infancy, raises serious concerns about potential long-term consequences for public health. The findings suggest that even low-level, chronic exposure during critical developmental windows could contribute to the rising prevalence of anxiety disorders and other neurodevelopmental issues observed in human populations.

Supporting Data and Context:

• Global Production and Use of Phthalates: Phthalates, including DEHP, are among the most widely produced and utilized chemicals globally. In 2015, the global market for phthalates was valued at approximately $14.7 billion, with DEHP being a significant contributor. This extensive production and use inevitably lead to widespread environmental contamination and human exposure.
• Biomonitoring Studies: Numerous biomonitoring studies have detected phthalate metabolites, including those of DEHP, in human urine samples across diverse populations. These studies consistently confirm pervasive exposure, with children often exhibiting higher levels due to their tendency to mouth objects and greater proximity to the floor where plasticizers can accumulate.
• Previous Research on DEHP and Neurodevelopment: Prior animal studies have linked DEHP exposure to alterations in neurotransmitter levels, including changes in dopamine and serotonin, which are critical for mood regulation and behavior. Some research has also suggested potential impacts on the development of brain regions involved in fear processing and emotional control.
• GABAergic System and Anxiety Disorders: The link between GABAergic dysfunction and anxiety disorders in humans is well-established. Many anxiolytic medications, such as benzodiazepines, exert their effects by enhancing GABAergic neurotransmission. This reinforces the plausibility of DEHP interfering with this crucial system.

Timeline of Research and Presentation:

The research presented at ENDO 2026 likely represents years of meticulous laboratory work, from the initial conception of the hypothesis to the execution of experiments, data analysis, and manuscript preparation. Scientific conferences serve as crucial venues for researchers to share preliminary findings and receive feedback from peers before formal publication in peer-reviewed journals. The presentation at ENDO 2026, held annually, signifies a critical point in the dissemination of this scientific discovery.

Potential Reactions from Related Parties:

• Environmental Health Organizations: Advocacy groups focused on environmental health and child safety are likely to view these findings as further evidence of the urgent need for stricter regulation of EDCs like DEHP. They may call for accelerated phase-outs of DEHP in consumer products, particularly those intended for children or medical use.
• Regulatory Agencies: Bodies such as the Environmental Protection Agency (EPA) in the United States and the European Chemicals Agency (ECHA) will likely review this research as part of ongoing risk assessments for DEHP. The findings could influence future regulatory decisions regarding acceptable exposure limits and restrictions on its use.
• Manufacturers of Plastic Products: Industries that utilize DEHP may face increased pressure to reformulate their products with alternative plasticizers. They might point to the complexities of chemical safety assessments and the need for comprehensive risk-benefit analyses, while potentially investing in research on safer alternatives.
• Medical Professionals: Clinicians, particularly pediatricians and endocrinologists, may become more vigilant in counseling pregnant women and parents about potential environmental exposures and the importance of choosing products with minimal chemical content.

Moving Forward: The Imperative for Precaution

The findings from the University of Buenos Aires study underscore the critical importance of the precautionary principle in chemical safety. Given the potential for irreversible developmental impacts, proactive measures to minimize exposure to endocrine-disrupting chemicals during vulnerable life stages are paramount. This research contributes to a growing body of evidence suggesting that the subtle, long-term effects of chemical exposures, often occurring at levels below acute toxicity thresholds, can have significant societal health implications.

Further research is needed to elucidate the precise molecular mechanisms by which DEHP disrupts neurodevelopment and to investigate the long-term consequences of such disruptions across the lifespan. Epidemiological studies in human populations exposed to DEHP during development would be invaluable in confirming and quantifying these risks. Ultimately, this study serves as a critical reminder of the intricate links between our environment, our endocrine systems, and our behavioral health, urging a reevaluation of our relationship with widely used industrial chemicals.